Abstract:Background: The genetic basis of Alzheimer disease (AD) in African American (AA) individuals is much less well understood than in European-ancestry (EA) individuals. Furthermore, relatively few AA donors have been included in postmortem AD studies. Methods: We generated transcriptome-wide bulk-level gene expression data derived from pre-frontal cortex (PFC) tissue obtained from 179 AA brain donors with a pathological diagnosis of AD or control. This sample was augmented by previously generated RNAseq data derived from PFC tissue from another group of 28 AA donors, yielding a total sample of 125 AD cases and 82 neuropathologically determined controls who were enrolled at 12 AD research centers across the United States. Expression of 33,611 genes was compared between AD cases and controls using LIMMA including covariates for age, sex, cell-type frequencies, and RNA integrity number. A false discovery rate corrected p-value (padj) was used to account for multiple testing. Gene-ontology (GO) term enrichment analysis was performed using GOseq. Results: Transcriptome-wide significant differential expression was observed with 482 genes among which the most significant, ADAMTS2, showed 1.52 times higher expression in AD cases compared to controls (p=2.96x10-8, padj=0.0010). Many of the differentially expressed genes are involved in mitochondrial energy production. Examination of differentially expressed genes observed previously in brain tissue from EA AD cases and controls revealed that 385 (35%) were nominally significant, 65 (5.8%) were significant after multiple test correction, and most (89%) had the same effect direction in the AA sample. Several other significant associations were not observed in the EA cohort, and these genes may be especially relevant to AD risk in the AA population (e.g., EFR3B, IRS4, and CA12). Examination of potential regulatory effects of AA GWAS-implicated AD risk variants identified several expression quantitative trait loci. Conclusions: In this first large-scale transcriptome-wide gene expression study of AD in brain from AA donors, we identified many differentially expressed genes, including ADAMTS2 which was recently reported to be differentially expressed in brain between pathologically confirmed EA AD cases with and without AD clinical symptoms. These results represent a substantial advance in knowledge about the genetic basis of AD in the AA population and suggest promising new targets for treatment.

Genome‐wide transcriptome analysis of Aβ deposition on PET in a Korean cohort

Tau pathway‐based gene analysis on PET identifies CLU and FYN in a Korean cohort

Ethnic differences in the prevalence of amyloid positivity and cognitive trajectories

Whole‐genome sequencing study in Koreans identifies novel loci for Alzheimer's disease

Plasma Alzheimer's disease biomarker variability: Amyloid‐independent and amyloid‐dependent factors

Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease

Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing

Transcriptome-wide association study of Alzheimer disease reveals many differentially expressed genes and multiple biological pathways in brain tissue from African American donors

MU-BRAIN: MUltiethnic Brain Rna-seq for Alzheimer INitiative

Large-scale Deep Proteomic Analysis in Alzheimer's Disease Brain Regions Across Race and Ethnicity

Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification

Large-scale Deep Proteomic Analysis in Alzheimer’s Disease Brain Regions Across Race and Ethnicity

Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology

Integrated spatial and single‐cell transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease

Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers

Blood-based Biomarkers for Alzheimer's Disease: a Multicenter-Based Cross-Sectional and Longitudinal Study in China.

Genome‐wide meta‐analysis identifies ancestry‐specific loci for Alzheimer's disease

Clinical Study of PET‐validated EEG‐machine learning algorithm predicting brain amyloid pathology in pre‐dementia Alzheimer’s disease

Identification of Key Transcriptome Biomarkers Based on a Vital Gene Module Associated with Pathological Changes in Alzheimer's Disease.

Long-read transcriptomic identification of synaptic adaptation to amyloid pathology in the App(NL-G-F) knock-in mouse model of the earliest phase of Alzheimer's disease

Prognostic plasma protein panel for Aβ deposition in the brain in Alzheimer’s disease